Patent intelligence · US
US 6462192
Processes for large scale production of tetrapyrroles
Processes for large scale production of tetrapyrroles
Patent details — US 6462192
- Jurisdiction
- US
- Status
- expired
- Grant date
- Oct 8, 2002
- Expiration
- Oct 3, 2022
- Applicant
- Miravant Pharmaceuticals, Inc.
- Claims
- 149
- CPC classes
- A61K, A61K41/0071
Quick answer
US 6462192 (Processes for large scale production of tetrapyrroles) is held by Miravant Pharmaceuticals, Inc.. Status: expired. Granted Oct 8, 2002. Expires Oct 3, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Miravant Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 149
- CPC classes
- A61K, A61K41/0071
More from Miravant Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 6462192?
US 6462192 (Processes for large scale production of tetrapyrroles) is held by Miravant Pharmaceuticals, Inc.. Status: expired. Granted Oct 8, 2002. Expires Oct 3, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6462192?
Miravant Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 6462192 expire?
Our index shows an expiration date of Oct 3, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.